Equities

Rhythm Biosciences Ltd

Rhythm Biosciences Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (AUD)0.067
  • Today's Change-0.001 / -1.47%
  • Shares traded207.64k
  • 1 Year change-84.96%
  • Beta2.3709
Data delayed at least 20 minutes, as of May 22 2024 02:49 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Rhythm Biosciences Limited is an Australia-based medical diagnostics company. The Company is engaged in the development and commercialization of Australian medical diagnostics technology for sale in domestic and international markets. The Company’s ColoSTAT a blood-base cancer test, designed for the early detection of colorectal cancer, has been developed initially as an alternative screening test for individuals unable to or unwilling to use available screening modalities. ColoSTAT is indicated to screen adults, aged 40 to 85, at average risk for developing Colorectal Cancer (CRC). The test-kit measures five specific biomarkers in the blood that either increase or decrease in quantity when CRC tumors are present.

  • Revenue in AUD (TTM)157.67k
  • Net income in AUD-8.63m
  • Incorporated2017
  • Employees--
  • Location
    Rhythm Biosciences LtdBio21 Institute30 Flemington Road, ParkvilleMELBOURNE 3010AustraliaAUS
  • Phone+61 39614-0600
  • Fax+61 39614-0550
  • Websitehttps://www.rhythmbio.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Patrys Ltd1.70m-5.12m14.40m15.00--2.87--8.50-0.0025-0.00250.00080.00240.1978--0.5828---59.77-43.96-68.99-47.06-----302.26-230.44----0.00---14.4540.52-4.15------
BTC Health Ltd16.03k-8.26m14.59m1.00--2.698.84909.89-0.0305-0.03050.000050.01670.0017--0.031---89.67-23.15-91.36-24.64-----51,522.02-2,498.18---0.07870.00---86.04-26.76-1,665.01------
Medlab Clinical Ltd943.67k-6.78m15.07m14.00------15.97-2.97-2.970.41330.56040.13012.2510.35---88.67-55.07-127.20-69.7590.4552.86-681.73-335.431.67-217.550.00---28.90-29.8318.55---30.00--
Amplia Therapeutics Ltd1.87m-4.46m16.02m1.00--0.7983--8.58-0.0224-0.02240.00940.07390.0949--0.7018---22.64-25.27-26.24-26.78-----238.69-342.26----0.1318---42.1012.31-71.30--31.88--
Argent BioPharma Ltd1.32m-17.02m16.53m----9.82--12.48-3.32-3.320.10030.03720.08130.70781.58---105.32-111.29-345.98-171.0521.8732.52-1,295.20-632.420.6561-24.850.4104---28.4147.31-2.34---16.20--
Radiopharm Theranostics Ltd0.00-46.82m16.57m----0.5521-----0.1343-0.13430.000.06520.00-------63.11---77.85-------------7.480.00-------13.78------
Oncosil Medical Ltd355.30k-11.71m16.59m2.00--2.56--46.68-0.0081-0.00810.00020.0020.0506--7.88---166.55-57.65-234.81-64.83-426.96---3,295.08-473.02---68.930.0256---59.92-37.72-5.74--40.13--
Auscann Group Holdings Ltd2.05m-9.44m17.60m27.00------8.59-0.0213-0.02170.00430.01620.1674--5.35---77.15-39.85-78.72-40.73100.59---460.74-925.91---23.160.00--13.8851.3757.10------
Rhythm Biosciences Ltd157.67k-8.63m18.27m----13.36--115.89-0.0386-0.03860.00070.00550.0263--1.81---144.00-106.11-169.71-125.51-1,899.74-1,210.71-5,473.20-6,642.262.04--0.0304--814.1828.776.55---20.43--
Algorae Pharmaceuticals Ltd84.10k-2.25m18.56m----5.12--220.70-0.0015-0.00150.000060.00220.0245--1.79---65.51-46.12-70.91-53.52-----2,678.04-591.05---136.750.00--1,132.26-44.06-7.68------
Acrux Ltd14.46m-709.00k18.61m43.00--3.29--1.29-0.0024-0.00240.05020.01951.29--4.86---6.34-39.91-9.21-46.0072.38---4.90-132.53----0.2861--133.7428.2992.23---16.66--
Chimeric Therapeutics Ltd0.00-11.31m20.55m----1.26-----0.027-0.0270.000.01910.00-------45.96---69.36-------------10.010.1596-------60.40------
Immuron Ltd3.58m-3.88m20.98m6.00--1.20--5.86-0.017-0.0170.01570.07690.16640.64687.92596,106.70-18.06-27.48-19.86-29.5880.8777.52-108.52-296.647.79-2.850.0023--135.85-13.34-32.66--3.27--
Noxopharm Ltd3.90m-12.13m21.04m1.00k--3.20--5.39-0.0415-0.04150.01340.02250.2684--1.643,901.84-83.43-50.96-94.78-62.98-----310.82-191.70---1.470.00--11.3244.0219.34------
Syntara Ltd9.83m-14.26m21.49m107.00--2.39--2.19-0.0197-0.01720.01360.00750.4421.582.22---64.13-27.33-97.76-34.2381.6988.37-145.11-61.991.75-262.590.0674--23.60-18.30-486.78---31.06--
Lumos Diagnostics Holdings Ltd12.27m-13.18m21.66m----1.57--1.76-0.0354-0.03540.03490.02870.34182.246.37---36.70-40.15-55.14-56.6759.7345.97-107.38-162.900.479-6.250.4803---9.4239.2980.38---38.50--
Data as of May 22 2024. Currency figures normalised to Rhythm Biosciences Ltd's reporting currency: Australian Dollar AUD

Institutional shareholders

4.09%Per cent of shares held by top holders
HolderShares% Held
FIL Investment Management (Hong Kong) Ltd.as of 31 Mar 202410.06m4.09%
Data from 31 Mar 2024 - 31 Mar 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.